Kenneth W Foreman

USPTO Granted Patents = 10 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 9.6

ph-index = 5

Forward Citations = 78(Granted Patents)

Company Filing History:

6 out of 118

Osi Pharmaceuticals, Inc.

Years Active: 2008-2022

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11291731 - Silicon based drug conjugates and methods of using same (2022-04-05),

2. 9931407 - Silicon based drug conjugates and methods of using same (2018-04-03),

3. 9096624 - Amino pyrimidine anticancer compounds (2015-08-04),

4. 8735405 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-05-27),

5. 8399433 - Amino pyrimidine anticancer compounds (2013-03-19),

6. 8101613 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2012-01-24),

7. 7820662 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2010-10-26),

8. 7674822 - PTP1b inhibitors (2010-03-09),

9. 7521473 - Inhibitors of protein tyrosine phosphatase 1B (2009-04-21),

10. 7459554 - Imidazopyrazine tyrosine kinase inhibitors (2008-12-02),

Title: The Innovations of Kenneth W. Foreman

Introduction

Kenneth W. Foreman is a notable inventor based in Syosset, NY (US), recognized for his contributions to the field of drug delivery systems. With a total of 10 patents to his name, Foreman's work focuses on innovative solutions that enhance the efficacy of therapeutic agents.

Latest Patents

One of Foreman's latest patents is titled "Silicon based drug conjugates and methods of using same." This invention describes silicon-based conjugates capable of delivering one or more payload moieties to a target cell or tissue. The contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that allows for the accumulation of the conjugate within a target cell or tissue, one or more payload moieties such as a therapeutic agent or imaging agent, and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

Career Highlights

Throughout his career, Kenneth W. Foreman has worked with prominent companies in the pharmaceutical industry, including Osi Pharmaceuticals, Inc. and Wyeth. His experience in these organizations has contributed significantly to his expertise in drug development and delivery systems.

Collaborations

Foreman has collaborated with notable professionals in his field, including Douglas S. Werner and Andrew Philip Crew. These collaborations have likely enriched his research and innovation efforts.

Conclusion

Kenneth W. Foreman stands out as an influential inventor in the realm of drug delivery systems, with a strong portfolio of patents that reflect his commitment to advancing medical technology. His work continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.